Abstract | BACKGROUND & OBJECTIVE: METHODS: RESULTS: Of the 32 patients, 8 achieved partial remission (PR), 8 had stable disease (SD), and 12 had progressive disease (PD)û the objective responses were not assessable (NA) in 4 patients. The response rate was 25.0%, and the clinical benefit response (CBR) rate was 46.9% (15 patients). The progression-free survival (PFS) was 4.7 months; the median overall survival was 8.6 months; the 1-year survival rate was 32.6%. The total occurrence rate of myelosuppression was 70.9%û the occurrence rate of grade III-IV myelosuppression was 32.3%: 12.9% for anemia, 19.4% for neutropenia, and 22.6% for thrombocytopenia. The occurrence rate of gastrointestinal adverse events was 56.2%û only 2 patients had grade III vomiting. Liver function damage (grade I-II) occurred in 8 (25.0%) patients; peripheral neurotoxicity (grade I) occurred in 14 (43.8%) patients. No chemotherapy-related death occurred. CONCLUSIONS: GEMOX is an effective regimen for pancreatic carcinoma with good clinical tolerance. The main adverse event is myelosuppression.
|
Authors | Yan-Xia Shi, Rui-Hua Xu, Wen-Qi Jiang, Li Zhang, Tong-Yu Lin, Yu-Hong Li, Zhong-Jun Xia, Hui-Yan Luo, Bing Han, Feng Wang, You-Jian He, Zhong-Zhen Guan |
Journal | Ai zheng = Aizheng = Chinese journal of cancer
(Ai Zheng)
Vol. 26
Issue 12
Pg. 1381-4
(Dec 2007)
China |
PMID | 18076807
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
- Organoplatinum Compounds
- Deoxycytidine
|
Topics |
- Adenocarcinoma
(drug therapy, pathology, secondary)
- Adult
- Aged
- Anemia
(chemically induced)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Deoxycytidine
(adverse effects, analogs & derivatives, therapeutic use)
- Disease-Free Survival
- Female
- Follow-Up Studies
- Humans
- Liver Neoplasms
(drug therapy, secondary)
- Male
- Middle Aged
- Nausea
(chemically induced)
- Neoplasm Staging
- Neutropenia
(chemically induced)
- Organoplatinum Compounds
(adverse effects, therapeutic use)
- Pancreatic Neoplasms
(drug therapy, pathology)
- Remission Induction
- Retrospective Studies
- Survival Rate
- Thrombocytopenia
(chemically induced)
- Vomiting
(chemically induced)
|